Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Everest Medicines Ltd. ( (HK:1952) ) has provided an announcement.
Everest Medicines chairman and executive director Yifang Wu has increased his stake in the company by purchasing 30,000 shares on the open market on 31 December 2025 for about HK$1.14 million, at an average price of roughly HK$37.98 per share. The board said the on-market share purchase reflects Wu’s strong confidence in the company’s long-term prospects and development, although it cautioned existing shareholders and potential investors to exercise care when trading the stock.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Limited is a biopharmaceutical company listed in Hong Kong that focuses on developing and commercializing innovative medicines, with its operations overseen by a board comprising executive, non-executive and independent non-executive directors.
Average Trading Volume: 3,605,589
Technical Sentiment Signal: Sell
Current Market Cap: HK$13.41B
Find detailed analytics on 1952 stock on TipRanks’ Stock Analysis page.